- Abivax shares surge as worries subside over immune drug’s cancer risk<figure><div><img src="https://imgproxy.divecdn.com/4eoVQHFTAvljHZA3dtwvKrrS1WlgcrV7_wLUFGcZYWw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjMwMTMxMDIyXzEua…BioPharma Dive · 23d ago↗ source
- Ipsen to scoop up Memo Therapeutics and its kidney infection drugIpsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...Endpoints · 23d ago↗ source
- A June flourish lifts biotech megaround tally in first half of 2026Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...